Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02235844 |
Recruitment Status :
Completed
First Posted : September 10, 2014
Last Update Posted : September 16, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Duchenne's Muscular Dystrophy | Biological: Umbilical Cord Mesenchymal Stem Cells | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD) |
Actual Study Start Date : | September 2014 |
Actual Primary Completion Date : | September 30, 2017 |
Actual Study Completion Date : | September 30, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Mesenchymal Stem Cells
Umbilical Cord Mesenchymal Stem Cells
|
Biological: Umbilical Cord Mesenchymal Stem Cells |
- Adverse Events [ Time Frame: 3 months after final treatment ]No occurrence of adverse events
- Change from baseline of weight [ Time Frame: 3 months after final treatment ]
- Change of muscle diameter (circumferential measurements) from baseline [ Time Frame: 3 months after final treatment ]
- Change from baseline of Pulmonary Maximum Expiratory Pressure [ Time Frame: 3 months after final treatment ]
- Change from baseline of Pulmonary Forced Vital Capacity [ Time Frame: 3 months after final treatment ]
- Maximum Change from baseline of Predicted Inspiratory Pressure % [ Time Frame: 3 months after final treatment ]
- Change from baseline of Predicted Maximum Expiratory Pressure % [ Time Frame: 3 months after final treatment ]
- Change from baseline of Predicted Forced Vital Capacity % [ Time Frame: 3 months after final treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 28 Years to 31 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Duchenne's Muscular Dystrophy
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02235844
United States, Kansas | |
Asthma and Allergy Consultants | |
Wichita, Kansas, United States, 67205 |
Principal Investigator: | Maurice HV Strickland, MD | Allergy and Asthma Consultants of Wichita, KS |
Responsible Party: | Allergy and Asthma Consultants, Wichita, Kansas |
ClinicalTrials.gov Identifier: | NCT02235844 |
Other Study ID Numbers: |
IND 16026 DMD Single Patient |
First Posted: | September 10, 2014 Key Record Dates |
Last Update Posted: | September 16, 2019 |
Last Verified: | September 2019 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Mesenchymal Stem Cells Umbilical Cord Duchenne's Muscular Dystrophy |
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked |